Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 155

1.

Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL).

Shanafelt TD, Kay NE, Parikh SA, Achenbach SJ, Lesnick CE, Hanson CA, Kleinstern G, Olson JE, Norman AD, Rabe KG, Schwager SM, Call TG, Slager SL.

Leukemia. 2020 Mar 18. doi: 10.1038/s41375-020-0799-8. [Epub ahead of print] No abstract available.

PMID:
32203143
2.

The impact of dose modification and temporary interruption of ibrutinib on outcomes of chronic lymphocytic leukemia patients in routine clinical practice.

Parikh SA, Achenbach SJ, Call TG, Rabe KG, Ding W, Leis JF, Kenderian SS, Chanan-Khan AA, Koehler AB, Schwager SM, Muchtar E, Fonder AL, McCullough KB, Nedved AN, Smith MD, Slager SL, Kay NE, Finnes HD, Shanafelt TD.

Cancer Med. 2020 Mar 18. doi: 10.1002/cam4.2998. [Epub ahead of print]

3.

Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis.

Bubik RJ, Barth DM, Hook C, Wolf RC, Muth JM, Mara K, Patnaik MS, Pruthi RK, Marshall AL, Litzow MR, Elliott MA, Hogan WJ, Shah MV, Begna KH, Alkhateeb H, Pardanani A, Ashrani AA, Call TG, Rivera CE, Camoriano JK, Go RS, Wolanskyj-Spinner AP, Parikh SA.

Leuk Lymphoma. 2020 Mar 11:1-9. doi: 10.1080/10428194.2020.1737684. [Epub ahead of print]

PMID:
32157935
4.

The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor.

Wang Y, Rabe KG, Bold MS, Shi M, Hanson CA, Schwager SM, Call TG, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Fonder AL, Chanan-Khan AA, Van Dyke DL, Slager SL, Kay NE, Ding W, Leis JF, Parikh SA.

Haematologica. 2020 Jan 23. pii: haematol.2019.240564. doi: 10.3324/haematol.2019.240564. [Epub ahead of print] No abstract available.

5.

Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare.

Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA.

Am J Hematol. 2020 Mar;95(3):E57-E60. doi: 10.1002/ajh.25690. Epub 2019 Dec 13. No abstract available.

PMID:
31788844
6.

Human Pegivirus Infection and Lymphoma Risk: A Systematic Review and Meta-analysis.

Fama A, Larson MC, Link BK, Habermann TM, Feldman AL, Call TG, Ansell SM, Liebow M, Xiang J, Maurer MJ, Slager SL, Nowakowski GS, Stapleton JT, Cerhan JR.

Clin Infect Dis. 2019 Oct 31. pii: ciz940. doi: 10.1093/cid/ciz940. [Epub ahead of print]

PMID:
31671178
7.

Association of elevated serumfree light chains with chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Clay-Gilmour AI, Rishi AR, Goldin LR, Greenberg-Worisek AJ, Achenbach SJ, Rabe KG, Maurer MJ, Kay NE, Shanafelt TD, Call TG, Brice Weinberg J, Camp NJ, Cerhan JR, Leis J, Norman A, Murray DL, Vincent Rajkumar S, Caporaso NE, Landgren O, McMaster ML, Slager SL, Vachon CM.

Blood Cancer J. 2019 Aug 5;9(8):59. doi: 10.1038/s41408-019-0220-x.

8.

Etiologies of Extreme Thrombocytosis: A Contemporary Series.

Hsieh RW, Ravindran A, Hook CC, Begna KH, Ashrani AA, Pruthi RK, Marshall AL, Hogan W, Litzow M, Hoyer J, Oliveira JL, Vishnu P, Call TG, Al-Kali A, Patnaik M, Gangat N, Pardanani A, Tefferi A, Go RS.

Mayo Clin Proc. 2019 Aug;94(8):1542-1550. doi: 10.1016/j.mayocp.2019.01.041.

PMID:
31378229
9.

Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center.

Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W.

Haematologica. 2020 Mar;105(3):765-773. doi: 10.3324/haematol.2019.224121. Epub 2019 Jun 13.

10.

Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice.

Hampel PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Witzig TE, Muchtar E, Leis JF, Chanan-Khan AA, Koehler AB, Fonder AL, Schwager SM, Slager SL, Shanafelt TD, Kay NE, Parikh SA.

Leuk Lymphoma. 2019 Nov;60(11):2712-2719. doi: 10.1080/10428194.2019.1602268. Epub 2019 Apr 24.

PMID:
31014142
11.

IGH translocations in chronic lymphocytic leukemia: Clinicopathologic features and clinical outcomes.

Fang H, Reichard KK, Rabe KG, Hanson CA, Call TG, Ding W, Kenderian SS, Muchtar E, Schwager SM, Leis JF, Chanan-Khan AA, Slager SL, Braggio E, Smoley SA, Kay NE, Shanafelt TD, Van Dyke DL, Parikh SA.

Am J Hematol. 2019 Mar;94(3):338-345. doi: 10.1002/ajh.25385. Epub 2019 Jan 8.

12.

Autoimmune cytopenias in patients with chronic lymphocytic leukaemia treated with ibrutinib in routine clinical practice at an academic medical centre.

Hampel PJ, Larson MC, Kabat B, Call TG, Ding W, Kenderian SS, Bowen D, Boysen J, Schwager SM, Leis JF, Chanan-Khan AA, Muchtar E, Hanson CA, Slager SL, Kay NE, Chaffee KG, Shanafelt TD, Parikh SA.

Br J Haematol. 2018 Nov;183(3):421-427. doi: 10.1111/bjh.15545. Epub 2018 Aug 16.

13.

Human Pegivirus infection and lymphoma risk and prognosis: a North American study.

Fama A, Xiang J, Link BK, Allmer C, Klinzman D, Feldman AL, Nowakowski GS, Liebow M, Larson MC, Maurer MJ, Ansell SM, Novak AJ, Asmann YW, Slager SL, Call TG, Habermann TM, Cerhan JR, Stapleton JT.

Br J Haematol. 2018 Sep;182(5):644-653. doi: 10.1111/bjh.15416. Epub 2018 May 29.

14.

PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.

He R, Ding W, Viswanatha DS, Chen D, Shi M, Van Dyke D, Tian S, Dao LN, Parikh SA, Shanafelt TD, Call TG, Ansell SM, Leis JF, Mai M, Hanson CA, Rech KL.

Am J Surg Pathol. 2018 Jul;42(7):843-854. doi: 10.1097/PAS.0000000000001077.

PMID:
29762141
15.

Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis.

Kleinstern G, Camp NJ, Goldin LR, Vachon CM, Vajdic CM, de Sanjose S, Weinberg JB, Benavente Y, Casabonne D, Liebow M, Nieters A, Hjalgrim H, Melbye M, Glimelius B, Adami HO, Boffetta P, Brennan P, Maynadie M, McKay J, Cocco PL, Shanafelt TD, Call TG, Norman AD, Hanson C, Robinson D, Chaffee KG, Brooks-Wilson AR, Monnereau A, Clavel J, Glenn M, Curtin K, Conde L, Bracci PM, Morton LM, Cozen W, Severson RK, Chanock SJ, Spinelli JJ, Johnston JB, Rothman N, Skibola CF, Leis JF, Kay NE, Smedby KE, Berndt SI, Cerhan JR, Caporaso N, Slager SL.

Blood. 2018 Jun 7;131(23):2541-2551. doi: 10.1182/blood-2017-11-814608. Epub 2018 Apr 19.

16.

Cumulative experience and long term follow-up of pentostatin-based chemoimmunotherapy trials for patients with chronic lymphocytic leukemia.

Kay NE, LaPlant BR, Pettinger AM, Call TG, Leis JF, Ding W, Parikh SA, Conte MJ, Bowen DA, Shanafelt TD.

Expert Rev Hematol. 2018 Apr;11(4):337-349. doi: 10.1080/17474086.2018.1442716. Epub 2018 Feb 26.

PMID:
29460654
17.

Outcomes of a large cohort of individuals with clinically ascertained high-count monoclonal B-cell lymphocytosis.

Parikh SA, Chaffee KG, Larson MC, Hampel PJ, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Conte MJ, Bowen D, Schwager SM, Slager SL, Hanson CA, Kay NE, Shanafelt TD.

Haematologica. 2018 Jun;103(6):e237-e240. doi: 10.3324/haematol.2017.183194. Epub 2018 Feb 1. No abstract available.

18.

Clinical and radiological responses to oral methotrexate alone or in combination with other agents in Erdheim-Chester disease.

Goyal G, Shah MV, Call TG, Hook CC, Hogan WJ, Go RS.

Blood Cancer J. 2017 Dec 15;7(12):647. doi: 10.1038/s41408-017-0034-7. No abstract available.

19.

Efficacy of biological agents in the treatment of Erdheim-Chester disease.

Goyal G, Shah MV, Call TG, Litzow MR, Wolanskyj-Spinner AP, Koster MJ, Tobin WO, Vassallo R, Ryu JH, Hook CC, Hogan WJ, Go RS.

Br J Haematol. 2018 Nov;183(3):520-524. doi: 10.1111/bjh.14997. Epub 2017 Oct 30. No abstract available.

PMID:
29082516
20.

Liver dysfunction in chronic lymphocytic leukemia: Prevalence, outcomes, and pathological findings.

Hampel PJ, Chaffee KG, King RL, Simonetto D, Larson MC, Achenbach S, Call TG, Ding W, Kenderian SS, Leis JF, Chanan-Khan AA, Bowen DA, Conte MJ, Schwager SM, Hanson CA, Slager SL, Kay NE, Shanafelt TD, Parikh SA.

Am J Hematol. 2017 Dec;92(12):1362-1369. doi: 10.1002/ajh.24915. Epub 2017 Oct 19.

21.

Risk of cutaneous T-cell lymphoma in patients with chronic lymphocytic leukemia and other subtypes of non-Hodgkin lymphoma.

Chang TW, Weaver AL, Shanafelt TD, Habermann TM, Wriston CC, Cerhan JR, Call TG, Brewer JD.

Int J Dermatol. 2017 Nov;56(11):1125-1129. doi: 10.1111/ijd.13653. Epub 2017 Jul 7.

22.

Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes.

Goyal G, Shah MV, Hook CC, Wolanskyj AP, Call TG, Rech KL, Go RS.

Br J Haematol. 2018 Aug;182(4):579-581. doi: 10.1111/bjh.14818. Epub 2017 Jun 27. No abstract available.

PMID:
28653448
23.

Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study.

Strati P, Parikh SA, Chaffee KG, Kay NE, Call TG, Achenbach SJ, Cerhan JR, Slager SL, Shanafelt TD.

Br J Haematol. 2017 Aug;178(3):394-402. doi: 10.1111/bjh.14785. Epub 2017 Jun 4.

24.

High prevalence of monoclonal gammopathy among patients with warm autoimmune hemolytic anemia.

Ravindran A, Sankaran J, Jacob EK, Kreuter JD, Hook CC, Gertz MA, Call TG, Pruthi RK, Litzow MR, Wolanskyj AP, Hogan WJ, Ashrani AA, Begna KH, Marshall AL, Kyle RA, Kay NE, Go RS.

Am J Hematol. 2017 Aug;92(8):E164-E166. doi: 10.1002/ajh.24765. Epub 2017 Jun 1. No abstract available.

25.

Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL.

Ding W, LaPlant BR, Call TG, Parikh SA, Leis JF, He R, Shanafelt TD, Sinha S, Le-Rademacher J, Feldman AL, Habermann TM, Witzig TE, Wiseman GA, Lin Y, Asmus E, Nowakowski GS, Conte MJ, Bowen DA, Aitken CN, Van Dyke DL, Greipp PT, Liu X, Wu X, Zhang H, Secreto CR, Tian S, Braggio E, Wellik LE, Micallef I, Viswanatha DS, Yan H, Chanan-Khan AA, Kay NE, Dong H, Ansell SM.

Blood. 2017 Jun 29;129(26):3419-3427. doi: 10.1182/blood-2017-02-765685. Epub 2017 Apr 19.

26.

CD49d associates with nodal presentation and subsequent development of lymphadenopathy in patients with chronic lymphocytic leukaemia.

Strati P, Parikh SA, Chaffee KG, Achenbach SJ, Slager SL, Call TG, Ding W, Jelinek DF, Hanson CA, Kay NE, Shanafelt TD.

Br J Haematol. 2017 Jul;178(1):99-105. doi: 10.1111/bjh.14647. Epub 2017 Apr 7.

27.

Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease.

Goyal G, Shah MV, Call TG, Litzow MR, Hogan WJ, Go RS.

JAMA Oncol. 2017 Sep 1;3(9):1253-1256. doi: 10.1001/jamaoncol.2017.0041.

28.

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.

Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, Holroyd A, Joseph V, Sunter NJ, Nieters A, Bea S, Monnereau A, Martin-Garcia D, Goldin LR, Clot G, Teras LR, Quintela I, Birmann BM, Jayne S, Cozen W, Majid A, Smedby KE, Lan Q, Dearden C, Brooks-Wilson AR, Hall AG, Purdue MP, Mainou-Fowler T, Vajdic CM, Jackson GH, Cocco P, Marr H, Zhang Y, Zheng T, Giles GG, Lawrence C, Call TG, Liebow M, Melbye M, Glimelius B, Mansouri L, Glenn M, Curtin K, Diver WR, Link BK, Conde L, Bracci PM, Holly EA, Jackson RD, Tinker LF, Benavente Y, Boffetta P, Brennan P, Maynadie M, McKay J, Albanes D, Weinstein S, Wang Z, Caporaso NE, Morton LM, Severson RK, Riboli E, Vineis P, Vermeulen RC, Southey MC, Milne RL, Clavel J, Topka S, Spinelli JJ, Kraft P, Ennas MG, Summerfield G, Ferri GM, Harris RJ, Miligi L, Pettitt AR, North KE, Allsup DJ, Fraumeni JF, Bailey JR, Offit K, Pratt G, Hjalgrim H, Pepper C, Chanock SJ, Fegan C, Rosenquist R, de Sanjose S, Carracedo A, Dyer MJ, Catovsky D, Campo E, Cerhan JR, Allan JM, Rothman N, Houlston R, Slager S.

Nat Commun. 2017 Feb 6;8:14175. doi: 10.1038/ncomms14175.

29.

Disseminated herpes zoster in chronic lymphocytic leukemia (CLL) patients treated with B-cell receptor pathway inhibitors.

Giridhar KV, Shanafelt T, Tosh PK, Parikh SA, Call TG.

Leuk Lymphoma. 2017 Aug;58(8):1973-1976. doi: 10.1080/10428194.2016.1267352. Epub 2016 Dec 14. No abstract available.

PMID:
27960571
30.

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia.

Grever MR, Abdel-Wahab O, Andritsos LA, Banerji V, Barrientos J, Blachly JS, Call TG, Catovsky D, Dearden C, Demeter J, Else M, Forconi F, Gozzetti A, Ho AD, Johnston JB, Jones J, Juliusson G, Kraut E, Kreitman RJ, Larratt L, Lauria F, Lozanski G, Montserrat E, Parikh SA, Park JH, Polliack A, Quest GR, Rai KR, Ravandi F, Robak T, Saven A, Seymour JF, Tadmor T, Tallman MS, Tam C, Tiacci E, Troussard X, Zent CS, Zenz T, Zinzani PL, Falini B.

Blood. 2017 Feb 2;129(5):553-560. doi: 10.1182/blood-2016-01-689422. Epub 2016 Nov 30.

31.

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL).

Shanafelt TD, Parikh SA, Noseworthy PA, Goede V, Chaffee KG, Bahlo J, Call TG, Schwager SM, Ding W, Eichhorst B, Fischer K, Leis JF, Chanan-Khan AA, Hallek M, Slager SL, Kay NE.

Leuk Lymphoma. 2017 Jul;58(7):1630-1639. doi: 10.1080/10428194.2016.1257795. Epub 2016 Nov 25.

PMID:
27885886
32.

A randomized phase II trial comparing chemoimmunotherapy with or without bevacizumab in previously untreated patients with chronic lymphocytic leukemia.

Kay NE, Strati P, LaPlant BR, Leis JF, Nikcevich D, Call TG, Pettinger AM, Lesnick CE, Hanson CA, Shanafelt TD.

Oncotarget. 2016 Nov 29;7(48):78269-78280. doi: 10.18632/oncotarget.13412.

33.

Pharmacovigilance during ibrutinib therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in routine clinical practice.

Finnes HD, Chaffee KG, Call TG, Ding W, Kenderian SS, Bowen DA, Conte M, McCullough KB, Merten JA, Bartoo GT, Smith MD, Leis J, Chanan-Khan A, Schwager SM, Slager SL, Kay NE, Shanafelt TD, Parikh SA.

Leuk Lymphoma. 2017 Jun;58(6):1376-1383. doi: 10.1080/10428194.2016.1251592. Epub 2016 Nov 8.

34.

Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

O'Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S.

Lancet Oncol. 2016 Oct;17(10):1409-1418. doi: 10.1016/S1470-2045(16)30212-1. Epub 2016 Sep 13.

PMID:
27637985
35.

Renal insufficiency is an independent prognostic factor in patients with chronic lymphocytic leukemia.

Strati P, Chaffee KG, Achenbach SJ, Slager SL, Leung N, Call TG, Ding W, Parikh SA, Kay NE, Shanafelt TD.

Haematologica. 2017 Jan;102(1):e22-e25. doi: 10.3324/haematol.2016.150706. Epub 2016 Sep 15. No abstract available.

36.

Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.

Strati P, Lanasa M, Call TG, Leis JF, Brander DM, LaPlant BR, Pettinger AM, Ding W, Parikh SA, Hanson CA, Chanan-Khan AA, Bowen DA, Conte M, Kay NE, Shanafelt TD.

Lancet Haematol. 2016 Sep;3(9):e407-14. doi: 10.1016/S2352-3026(16)30064-3. Epub 2016 Aug 1.

PMID:
27570087
37.

A population-based study of large granular lymphocyte leukemia.

Shah MV, Hook CC, Call TG, Go RS.

Blood Cancer J. 2016 Aug 5;6(8):e455. doi: 10.1038/bcj.2016.59.

38.

Meta-analysis of genome-wide association studies discovers multiple loci for chronic lymphocytic leukemia.

Berndt SI, Camp NJ, Skibola CF, Vijai J, Wang Z, Gu J, Nieters A, Kelly RS, Smedby KE, Monnereau A, Cozen W, Cox A, Wang SS, Lan Q, Teras LR, Machado M, Yeager M, Brooks-Wilson AR, Hartge P, Purdue MP, Birmann BM, Vajdic CM, Cocco P, Zhang Y, Giles GG, Zeleniuch-Jacquotte A, Lawrence C, Montalvan R, Burdett L, Hutchinson A, Ye Y, Call TG, Shanafelt TD, Novak AJ, Kay NE, Liebow M, Cunningham JM, Allmer C, Hjalgrim H, Adami HO, Melbye M, Glimelius B, Chang ET, Glenn M, Curtin K, Cannon-Albright LA, Diver WR, Link BK, Weiner GJ, Conde L, Bracci PM, Riby J, Arnett DK, Zhi D, Leach JM, Holly EA, Jackson RD, Tinker LF, Benavente Y, Sala N, Casabonne D, Becker N, Boffetta P, Brennan P, Foretova L, Maynadie M, McKay J, Staines A, Chaffee KG, Achenbach SJ, Vachon CM, Goldin LR, Strom SS, Leis JF, Weinberg JB, Caporaso NE, Norman AD, De Roos AJ, Morton LM, Severson RK, Riboli E, Vineis P, Kaaks R, Masala G, Weiderpass E, Chirlaque MD, Vermeulen RCH, Travis RC, Southey MC, Milne RL, Albanes D, Virtamo J, Weinstein S, Clavel J, Zheng T, Holford TR, Villano DJ, Maria A, Spinelli JJ, Gascoyne RD, Connors JM, Bertrand KA, Giovannucci E, Kraft P, Kricker A, Turner J, Ennas MG, Ferri GM, Miligi L, Liang L, Ma B, Huang J, Crouch S, Park JH, Chatterjee N, North KE, Snowden JA, Wright J, Fraumeni JF, Offit K, Wu X, de Sanjose S, Cerhan JR, Chanock SJ, Rothman N, Slager SL.

Nat Commun. 2016 Mar 9;7:10933. doi: 10.1038/ncomms10933.

39.

Prevalence and characteristics of central nervous system involvement by chronic lymphocytic leukemia.

Strati P, Uhm JH, Kaufmann TJ, Nabhan C, Parikh SA, Hanson CA, Chaffee KG, Call TG, Shanafelt TD.

Haematologica. 2016 Apr;101(4):458-65. doi: 10.3324/haematol.2015.136556. Epub 2016 Jan 27.

40.

Effect of Non-Hodgkin Lymphoma on Survival in Patients With Malignant Fibrous Histiocytoma, Kaposi Sarcoma, and Sebaceous Carcinoma: A SEER Population-Based Study.

Brewer JD, Shanafelt TD, Cerhan JR, Call TG, Weaver AL, Otley CC.

Dermatol Surg. 2016 Jan;42 Suppl 1:S32-9. doi: 10.1097/DSS.0000000000000520.

PMID:
26730972
41.

Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with everolimus (RAD001) and alemtuzumab: a Phase I/II study.

Zent CS, Bowen DA, Conte MJ, LaPlant BR, Call TG.

Leuk Lymphoma. 2016 Jul;57(7):1585-91. doi: 10.3109/10428194.2015.1113280. Epub 2015 Dec 24.

PMID:
26699397
42.

A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908).

Zent CS, Victoria Wang X, Ketterling RP, Hanson CA, Libby EN, Barrientos JC, Call TG, Chang JE, Liu JJ, Calvo AR, Lazarus HM, Rowe JM, Luger SM, Litzow MR, Tallman MS.

Am J Hematol. 2016 Mar;91(3):308-12. doi: 10.1002/ajh.24265. Epub 2016 Feb 9.

43.

Solid organ transplant in individuals with monoclonal B-cell lymphocytosis and chronic lymphocytic leukaemia.

Strati P, Gharaibeh KA, Leung N, Cosio FG, Call TG, Shanafelt TD.

Br J Haematol. 2016 Jul;174(1):162-5. doi: 10.1111/bjh.13759. Epub 2015 Oct 5. No abstract available.

PMID:
26436615
44.

Impact of Alemtuzumab Therapy and Route of Administration in T-Prolymphocytic Leukemia: A Single-Center Experience.

Damlaj M, Sulai NH, Oliveira JL, Ketterling RP, Hashmi S, Witzig T, Nowakowski G, Call TG, Shanafelt TD, Ding W, Hogan WJ, Litzow MR, Patnaik MM.

Clin Lymphoma Myeloma Leuk. 2015 Nov;15(11):699-704. doi: 10.1016/j.clml.2015.07.643. Epub 2015 Aug 5.

PMID:
26422251
45.

Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis.

Solomon BM, Chaffee KG, Moreira J, Schwager SM, Cerhan JR, Call TG, Kay NE, Slager SL, Shanafelt TD.

Leukemia. 2016 Feb;30(2):331-6. doi: 10.1038/leu.2015.235. Epub 2015 Aug 27.

46.

Renal complications in chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis: the Mayo Clinic experience.

Strati P, Nasr SH, Leung N, Hanson CA, Chaffee KG, Schwager SM, Achenbach SJ, Call TG, Parikh SA, Ding W, Kay NE, Shanafelt TD.

Haematologica. 2015 Sep;100(9):1180-8. doi: 10.3324/haematol.2015.128793. Epub 2015 Jun 18.

47.

Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: Natural history, clinical correlates, and outcomes.

Parikh SA, Leis JF, Chaffee KG, Call TG, Hanson CA, Ding W, Chanan-Khan AA, Bowen D, Conte M, Schwager S, Slager SL, Van Dyke DL, Jelinek DF, Kay NE, Shanafelt TD.

Cancer. 2015 Sep 1;121(17):2883-91. doi: 10.1002/cncr.29438. Epub 2015 Apr 30.

48.

Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.

Shanafelt TD, Borah BJ, Finnes HD, Chaffee KG, Ding W, Leis JF, Chanan-Khan AA, Parikh SA, Slager SL, Kay NE, Call TG.

J Oncol Pract. 2015 May;11(3):252-8. doi: 10.1200/JOP.2014.002469. Epub 2015 Mar 24.

PMID:
25804983
49.

Increased incidence of malignant melanoma and other rare cutaneous cancers in the setting of chronic lymphocytic leukemia.

Brewer JD, Shanafelt TD, Call TG, Cerhan JR, Roenigk RK, Weaver AL, Otley CC.

Int J Dermatol. 2015 Aug;54(8):e287-93. doi: 10.1111/ijd.12564. Epub 2015 Mar 13.

PMID:
25772131
50.

The efficacy of ibrutinib in the treatment of Richter syndrome.

Tsang M, Shanafelt TD, Call TG, Ding W, Chanan-Khan A, Leis JF, Nowakowski GS, Bowen D, Conte M, Schwager SM, Slager SL, Kay NE, Hanson CA, Parikh SA.

Blood. 2015 Mar 5;125(10):1676-8. doi: 10.1182/blood-2014-12-610782. No abstract available.

Supplemental Content

Support Center